Rian J Dickstein1, Mark F Munsell2, Lance C Pagliaro3, Curtis A Pettaway1. 1. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
OBJECTIVE: To describe both clinical and pathological response rates, survival, and predictors of survival when using contemporary perioperative chemotherapy and surgical resection for patients with regionally advanced squamous cell carcinoma (SCC) of the penis. PATIENTS AND METHODS: Retrospective review of all patients diagnosed with SCC of the penis and regional lymph node metastases that were treated with chemotherapy with the intent to undergo lymphadenectomy. Clinical and pathological responses were reported. Recurrence-free and overall survival was estimated using Kaplan-Meier analysis. Cox proportional hazards regression was used to assess factors for survival. RESULTS: In all, 61 patients were identified, of which 54 (90%) received chemotherapy with paclitaxel/ifosfamide/cisplatin. In all, 39 patients (65%) had either a partial (PR) or complete response (CR) to chemotherapy. The 5-year survival varied significantly (P = 0.045-0.001) among patients achieving a CR/PR (50%), stable disease (25%), and progression (7.7%). In all, 10 patients (16.4%) were rendered pN0 with combined therapy and 20 patients (33%) were alive and disease free at a median follow-up of 67 months, while 32 (52%) died from disease. Long-term survival was associated with response to chemotherapy and favourable pathological findings after resection. CONCLUSION: Contemporary chemotherapy resulted in clinically significant responses among patients with regionally advanced penile cancer. About 50% of such patients with an objective response to chemotherapy who undergo consolidative lymphadenectomy will remain alive at 5 years.
OBJECTIVE: To describe both clinical and pathological response rates, survival, and predictors of survival when using contemporary perioperative chemotherapy and surgical resection for patients with regionally advanced squamous cell carcinoma (SCC) of the penis. PATIENTS AND METHODS: Retrospective review of all patients diagnosed with SCC of the penis and regional lymph node metastases that were treated with chemotherapy with the intent to undergo lymphadenectomy. Clinical and pathological responses were reported. Recurrence-free and overall survival was estimated using Kaplan-Meier analysis. Cox proportional hazards regression was used to assess factors for survival. RESULTS: In all, 61 patients were identified, of which 54 (90%) received chemotherapy with paclitaxel/ifosfamide/cisplatin. In all, 39 patients (65%) had either a partial (PR) or complete response (CR) to chemotherapy. The 5-year survival varied significantly (P = 0.045-0.001) among patients achieving a CR/PR (50%), stable disease (25%), and progression (7.7%). In all, 10 patients (16.4%) were rendered pN0 with combined therapy and 20 patients (33%) were alive and disease free at a median follow-up of 67 months, while 32 (52%) died from disease. Long-term survival was associated with response to chemotherapy and favourable pathological findings after resection. CONCLUSION: Contemporary chemotherapy resulted in clinically significant responses among patients with regionally advanced penile cancer. About 50% of such patients with an objective response to chemotherapy who undergo consolidative lymphadenectomy will remain alive at 5 years.
Authors: Shreyas S Joshi; Elizabeth Handorf; David Strauss; Andres F Correa; Alexander Kutikov; David Y T Chen; Rosalia Viterbo; Richard E Greenberg; Robert G Uzzo; Marc C Smaldone; Daniel M Geynisman Journal: JAMA Oncol Date: 2018-05-01 Impact factor: 31.777
Authors: Andrea Necchi; Gregory R Pond; Daniele Raggi; Sarah R Ottenhof; Rosa S Djajadiningrat; Simon Horenblas; Vincent Khoo; Oliver W Hakenberg; Desiree Draeger; Chris Protzel; Axel Heidenreich; Friederike Haidl; Bernie J Eigl; Lucia Nappi; Kazumasa Matsumoto; Ulka Vaishampayan; Michael E Woods; Roberto Salvioni; Nicola Nicolai; Mario Catanzaro; Patrizia Giannatempo; Daniel M Geynisman; Mirko Preto; Evanguelos Xylinas; Matthew I Milowsky; Sabino De Placido; Giuseppe Di Lorenzo; Guru Sonpavde Journal: Clin Genitourin Cancer Date: 2017-02-27 Impact factor: 2.872
Authors: F A Distler; S Pahernik; G Gakis; G Hutterer; S Lebentrau; M Rink; P Nuhn; S Brookman-May; M Burger; C Gratzke; I Wolff; M May Journal: World J Urol Date: 2019-12-13 Impact factor: 4.226
Authors: Oliver Walther Hakenberg; Desiree Louise Dräger; Andreas Erbersdobler; Carsten Maik Naumann; Klaus-Peter Jünemann; Chris Protzel Journal: Dtsch Arztebl Int Date: 2018-09-28 Impact factor: 5.594
Authors: Andrej Panic; Henning Reis; Alina Wittka; Christopher Darr; Boris Hadaschik; Verena Jendrossek; Diana Klein Journal: Front Oncol Date: 2021-03-31 Impact factor: 6.244
Authors: Jad Chahoud; William Paul Skelton; Philippe E Spiess; Christine Walko; Jasreman Dhillon; Kenneth L Gage; Peter A S Johnstone; Rohit K Jain Journal: Front Oncol Date: 2020-12-23 Impact factor: 6.244
Authors: Carlos E Stecca; Marie Alt; Di Maria Jiang; Peter Chung; Juanita M Crook; Girish S Kulkarni; Srikala S Sridhar Journal: Oncol Ther Date: 2021-01-16